21 hours ago · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech ...

4 days ago · Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

20 hours ago · Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement Bloomberg Terminal It had offered 17.2 million shares for $15 to $17 each.

21 hours ago · Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments. Quiver AI Summary. Metsera, Inc., a clinical-stage biotechnology company specializing ...

The IPO valued the drug developer at $1.8 billion, ahead of its Nasdaq market debut. The global weight-loss drug market, expected to be worth about $150 billion by the early 2030s, has drawn ...

1 day ago · The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public. ... Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday. ...

3 days ago · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is offering over 17 million shares priced between $15 and $17 for its Nasdaq listing. The biotech is targeting $250.8m based on the midpoint of the price ...

3 days ago · Metsera intends to raise $275 million in gross proceeds from an IPO of its common stock, offering approximately 17.19 million shares at a proposed midpoint price of $16.00 per share.

4 days ago · This morning also saw Maze Therapeutics outline plans for a $131 million IPO, while Hong Kong-listed Ascentage Pharma joined the Nasdaq via a $126.4 million offering on Friday.. Metsera plans to ...

4 days ago · Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies. The New York-based firm plans to ...